Literature DB >> 17876646

Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.

K Vandevyvere1, F P Luyten1, P Verschueren1, R Lories1, S Segaert2, R Westhovens3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17876646     DOI： 10.1007/s10067-007-0733-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  15 in total

1.  Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept.

Authors:  Christopher Sacher; Andrea Rubbert; Cathrin König; Karin Scharffetter-Kochanek; Thomas Krieg; Nicolas Hunzelmann
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

2.  Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.

Authors:  Alessandro Zaccagna; Alberto Bertone; Paolo Puiatti; Franco Picciotto; Tatiana Sprujevnik; Renato Santucci; Francesco Paolo Rossini
Journal:  Eur J Dermatol       Date:  2003 May-Jun       Impact factor: 3.328

3.  Treatment of multicentric reticulohistiocytosis with etanercept.

Authors:  Bradley T Kovach; Kenneth T Calamia; John S Walsh; William W Ginsburg
Journal:  Arch Dermatol       Date:  2004-08

4.  Infliximab as a treatment for recalcitrant pyoderma gangrenosum.

Authors:  M Singh; S M Andrew; J T Lear
Journal:  Clin Exp Dermatol       Date:  2004-03       Impact factor: 3.470

5.  Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.

Authors:  V J Swale; M Saha; N Kapur; A V Hoffbrand; M H A Rustin
Journal:  Clin Exp Dermatol       Date:  2005-03       Impact factor: 3.470

6.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

7.  Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.

Authors:  T Ljung; M Staun; O Grove; O Fausa; M H Vatn; P M Hellström
Journal:  Scand J Gastroenterol       Date:  2002-09       Impact factor: 2.423

Review 8.  Bacterial superantigens and inflammatory skin diseases.

Authors:  L Skov; O Baadsgaard
Journal:  Clin Exp Dermatol       Date:  2000-01       Impact factor: 3.470

9.  Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.

Authors:  M Kloppenburg; F C Breedveld; J P Terwiel; C Mallee; B A Dijkmans
Journal:  Arthritis Rheum       Date:  1994-05

10.  Adalimumab therapy for recalcitrant pyoderma gangrenosum.

Authors:  Margaret A Fonder; Deborah L Cummins; Benjamin D Ehst; Grant J Anhalt; Jon H Meyerle
Journal:  J Burns Wounds       Date:  2006-11-20
View more
  8 in total

Review 1.  Biological therapy for dermatological manifestations of inflammatory bowel disease.

Authors:  Maddalena Zippi; Roberta Pica; Daniela De Nitto; Paolo Paoluzi
Journal:  World J Clin Cases       Date:  2013-05-16       Impact factor: 1.337

Review 2.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

3.  Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.

Authors:  Rahul Sehgal; Erik J Stratman; Jonathan E Cutlan
Journal:  Clin Med Res       Date:  2018-04-02

4.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 5.  Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab.

Authors:  Anastasia Skalkou; Sofia-Magdalini Manoli; Alexandros Sachinidis; Vasilios Ntouros; Konstantinos Petidis; Eleni Pagkopoulou; Efstratios Vakirlis; Athina Pyrpasopoulou; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2017-10-26       Impact factor: 2.631

Review 6.  Colitis associated with biological agents.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

7.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

Review 8.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.